Amphastar Pharmaceuticals (AMPH) Interest & Investment Income (2013 - 2026)

Amphastar Pharmaceuticals' Interest & Investment Income history runs 14 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 14.89% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $9.0 million, a 11.38% decrease from a year earlier, with the FY2025 full-year figure at $8.7 million, down 18.22% from the prior year.
• Interest & Investment Income retreated to $2.4 million in Q1 2026 per AMPH's latest filing, from $2.4 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $3.3 million in Q2 2024 and bottomed at $181000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $2.1 million (2025), against an average of $1.7 million.
• Across the five-year window, Interest & Investment Income soared 410.5% in 2023 and plunged 42.43% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $580000.0 in 2022, then soared by 297.07% to $2.3 million in 2023, then retreated by 0.48% to $2.3 million in 2024, then advanced by 5.72% to $2.4 million in 2025, then decreased by 0.95% to $2.4 million in 2026.
• Per Business Quant, the three latest AMPH Interest & Investment Income figures stand at $2.4 million (Q1 2026), $2.4 million (Q4 2025), and $2.2 million (Q3 2025).